Moore Capital Management LP Takes $756,000 Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Moore Capital Management LP purchased a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 20,998 shares of the medical device company's stock, valued at approximately $756,000.

Other institutional investors have also modified their holdings of the company. AlphaQuest LLC boosted its position in Tandem Diabetes Care by 138.7% during the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock worth $34,000 after acquiring an additional 541 shares during the last quarter. Jones Financial Companies Lllp boosted its holdings in Tandem Diabetes Care by 195.8% in the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock valued at $41,000 after purchasing an additional 748 shares during the last quarter. Assetmark Inc. boosted its holdings in Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after purchasing an additional 535 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after purchasing an additional 1,101 shares during the last quarter. Finally, Venturi Wealth Management LLC boosted its holdings in Tandem Diabetes Care by 5,955.9% in the 4th quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company's stock valued at $74,000 after purchasing an additional 2,025 shares during the last quarter.

Tandem Diabetes Care Stock Up 1.7%

TNDM traded up $0.38 during trading hours on Friday, hitting $23.08. 1,111,848 shares of the company's stock were exchanged, compared to its average volume of 1,502,046. Tandem Diabetes Care, Inc. has a 12-month low of $15.75 and a 12-month high of $53.69. The firm has a 50 day moving average of $19.13 and a 200 day moving average of $27.87. The firm has a market cap of $1.54 billion, a P/E ratio of -11.96 and a beta of 1.47. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business had revenue of $234.42 million for the quarter, compared to analysts' expectations of $220.19 million. During the same period in the previous year, the company earned ($0.65) earnings per share. Tandem Diabetes Care's quarterly revenue was up 22.3% on a year-over-year basis. Analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Insider Buying and Selling

In other news, COO Jean-Claude Kyrillos purchased 10,538 shares of the stock in a transaction on Friday, March 7th. The stock was bought at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the acquisition, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at approximately $190,948.56. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have weighed in on TNDM. Citigroup lowered shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and decreased their target price for the company from $35.00 to $24.00 in a report on Tuesday, March 4th. Royal Bank of Canada decreased their target price on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a report on Thursday, February 27th. Mizuho assumed coverage on shares of Tandem Diabetes Care in a report on Thursday, April 10th. They issued a "neutral" rating and a $20.00 target price on the stock. Stifel Nicolaus reduced their price target on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Finally, Canaccord Genuity Group boosted their price target on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the company a "buy" rating in a research note on Thursday, May 1st. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $39.81.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.